Graeme Sloan – Managing Director – Kali Metals (ASX:KM1) is a portfolio of assets that represents one of the largest and most prospective exploration packages across Australia’s world leading hard-rock lithium fields.
Copyright 2024 – Finance News Network
Source: Finance News Network
26 Sep 2022 - European Metals Holdings Limited (ASX:EMH) discusses its Cinovec project, the largest hard rock lithium resource in Europe.
Read More03 Mar 2020 - Catapult Limited (ASX:CAT) CEO, Will Lopes discusses 1H20 results and outlook.
Read More24 Oct 2019 - BluGlass Limited (ASX:BLG) Managing Director and CEO, Giles Bourne, discusses the launch of the company's new laser diode business and how this fits into its strategy.
Read More25 Mar 2024 - Clean TeQ Water (ASX:CNQ) CEO Peter Voigt provides an overview of the company, discussing solutions for the global scarcity in water.
Read More15 Apr 2024 - Discover how Hiremii, led by CEO Andrew Hornby, is reshaping recruitment with AI technology. Explore their innovative approach to revolutionize hiring processes.
Read More16 Mar 2022 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes discuses the company's recent sales win and its distribution agreement with distributor Thermo Fisher Scientific.
Read More03 Dec 2019 - Synertec Corporation Limited (ASX:SOP) Managing Director, Michael Carroll & CFO, David Harris talk FY19 results, market conditions and the outlook for specialist engineering and compliance services.
Read More27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.
Read More24 May 2021 - BluGlass Limited (ASX:BLG) Non-Executive Director Jean-Michel Pelaprat talks about joining BluGlass, his experience, and the future for BluGlass's gallium nitride technology.
Read More24 Jun 2020 - Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.
Read More
